RESUMO
Sarcopenic obesity has become a significant age-related metabolic problem. Catechins are flavanol, derivatives which poses a strong antioxidant activity. The major components of catechin derivatives. were identified through our physicochemical and pharmacokinetic parameters estimation. Therefore, in this study, network pharmacology was used to explore the multiple targets related to Sarcopenia, Metabolic syndrome, and obesity. The targets were identified from network analysis. The catechin derivatives were screened using Lipinski's rule of five, Veber scale, Egan scale, and Muegge scale. From this drugglikness property catechin and Epicatechin was selected which were docked towards the myostatin inhibition PDB ID: 3HH2. Furthermore, the computational docking method on Catechin and Epicatechin with the stronger interaction towards myostatin inhibition receptor with the binding energy of -6.90 kcal/mol. and -7.0 kcal/mol from autodock software, respectively, for catechin and Epicatechin. Higher binding energy confirms the pharmacotherapeutic activity of Catechin and Epicatechin toward the myostatin inhibitor target.
Assuntos
Catequina , Sarcopenia , Humanos , Catequina/farmacologia , Catequina/química , Miostatina/metabolismo , Farmacologia em Rede , Obesidade/tratamento farmacológico , Simulação de Acoplamento MolecularRESUMO
In this study, we evaluated the potential of curated structurally modified chalcone derivatives as anti-tuberculosis (TB) agents through computer-aided drug design. Compounds from the flavonoid family known as chalcones were identified by the chemical group 1,3-diaryl-2-propen-1-one. After a search of the literature, 14 outstanding structurally modified chalcones were selected and evaluated for inhibitory activity against Mycobacterium tuberculosis H37Rv targets. The therapeutic potential of the chalcones was directly based on the drug-likeness and pharmacokinetic properties of the synthesized compounds. Prompt drug selection and personalized therapy are required to prevent TB from progressing and spreading to others. Pharmacokinetic parameters helps in the identification of lead molecule, at the earlier stages of drug development.
Assuntos
Chalcona , Chalconas , Mycobacterium tuberculosis , Tuberculose , Humanos , Chalcona/farmacologia , Chalcona/química , Chalconas/farmacologia , Chalconas/química , Tuberculose/tratamento farmacológico , Antituberculosos/farmacologia , Antituberculosos/químicaRESUMO
Guggulsterone plays a significant role in cholesterol-lowering by inhibiting Farnesoid X Receptor. The present study aims to identify the isomers of Guggulsterone with high binding affinity and good binding interaction with targeted protein and positive control atorvastatin. The pharmacokinetic parameters of Guggulsterone isomers were estimated from P.K.C.S.M. online server, and molecular docking analysis was performed from Autodock V.® 4.2.6 Program. From the computer-aided drug designing, we have confirmed that guggulsterone isomers are inhibitors of the CYP3A4 enzyme and hepatotoxic. Guggulsterone isomer showed a stronger binding affinity when compared with atorvastatin. The docking score for Guggulsterone was -9.28 kcal/mol, E-Guggulsterone -9.56 kcal/mol, Z-Guggulsterone -9.79 kcal/mol, M-Guggulsterone -9.45 kcal/mol, and positive control atorvastatin -8.26 kcal/mol. The present study revealed that the isomers of Guggulsterone have high binding affinity and good binding interaction with targeted proteins.
RESUMO
In this study, the catechin structure was modified with Halogen and Nitrogen base at C-6 and C-8 Positions in Ring A. Pharmacokinetic parameters affirm the drug-likeness property of the designed compounds. Molecular Docking was performed for all the compounds towards the myostatin inhibition target (PDB: 3HH2). Such desirable quality of modified Catechin will create a spark in the novel drug discovery using acting as a bioenhancer. As a result, the present research is aimed to offer an overview of the structural simulation of Cl, F, I, NH2, NO2, and Br at C-6 and C-8 positions in A Ring A of Catechin. This preliminary evidence creates an impact on the novelsemi0synthetic drug discovery for the therapeutic management of sarcopenia.
RESUMO
Polyphenols, the important secondary metabolites, consist of multiple phytochemicals and show numerous physiological effects. Flavones play a significant role in various chronic disorders such as diabetes.. In this study, all the flavones were encountered, and it was further filtered based on their drug-likeness properties and pharmacokinetic parameters. Existing literature confirms that flavone-based compounds are suitable as the drug of choice in sarcopenic obesity. A molecular docking study was performed toward the myostatin inhibition profile of the flavones using PDB:3HH2 as a target site. This computer-aided drug design helps select lead molecules in novel drug discovery.